# A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06827613/  
OnCo record `nct06827613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sacituzumab govitecan in advanced solid tumours, run by Marengo Therapeutics, Inc., now recruiting.

## Summary

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06827613 by Marengo Therapeutics, Inc., with 50 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-01. Interventions recorded: STAR0602 and Sacituzumab Govitecan (SG).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06827613
- Phase: 1/2
- Setting: A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)
- Sponsor: Marengo Therapeutics, Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06827613: https://clinicaltrials.gov/study/NCT06827613

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Marengo Therapeutics](https://onco.cc/companies/marengo-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06827613.json